SAFETY AND IMMUNOGENICITY OF A COMBINED LIVE ATTENUATED MEASLES, MUMPS, RUBELLA, AND VARICELLA VACCINE (MMT(II)V) IN HEALTHY-CHILDREN

An investigational tetravalent combined measles, mumps, rubella, and v aricella vaccine and measles-mumps-rubella and varicella vaccines at s eparate injection sites given at the same visit were evaluated with re spect to safety and cell-mediated and humoral immune responses at 6 we eks and 1 year after vaccination. Varicella seroconversion rates and l ymphocyte proliferation responses were 100% for both vaccine groups at 6 weeks and 1 year. However, the antibody titer to varicella was lowe r in the combined vaccine group at 6 weeks, but there was no statistic al difference in cell-mediated immune responses. One-year geometric me an titers were not statistically different, Seroconversion rates for m easles, mumps, and rubella were 100% for both vaccine groups at 6 week s and 1 year. Long-term follow-up of these immune responses is planned .